Search Site
  • 0
    My Cart

    Click Here to Find How Many Items You Have Added:)

    image loader

    Adding item(s) to cart......

Home >> Signaling Pathways >> TGF-β / Smad Signaling >> Bcr-Abl

Bcr-Abl

Bcl-Abl is a constitutively activated chimeric tyrosine kinase which is the genetic abnormality expressed in patient with CML (chronic myeloid leukemia).

Products for  Bcr-Abl

  1. Cat.No. Product Name Information
  2. GC12172 1-Naphthyl PP1

    1NaphthylPP1, PP1 Analog

     Src family kinases inhibitor 1-Naphthyl PP1 Chemical Structure
  3. GC15579 Adaphostin

    NSC 680410

     P210bcr/abl tyrosine kinase inhibitor Adaphostin Chemical Structure
  4. GC73739 AKE-72 AKE-72 (compound 5) is a potent inhibitor of Pan-BCR-ABL. AKE-72 Chemical Structure
  5. GC32703 Asciminib (ABL001)

    ABL001

     Asciminib (ABL001) (ABL001) is a potent and selective allosteric BCR-ABL1 inhibitor, which inhibits Ba/F3 cells grown with an IC50 of 0.25 nM. Asciminib (ABL001) Chemical Structure
  6. GC64462 Asciminib hydrochloride Asciminib (ABL001) hydrochloride is a potent and selective allosteric BCR-ABL1 inhibitor, which inhibits Ba/F3 cells grown with an IC50 of 0.25 nM. Asciminib hydrochloride Chemical Structure
  7. GC35462 Bafetinib

    INNO-406

    Bcr-Abl/Lyn tyrosine kinase inhibitor

     Bafetinib Chemical Structure
  8. GC33343 BCR-ABL-IN-1 BCR-ABL-IN-1 is an inhibitor of BCR-ABL tyrosine kinase, with a pIC50 of 6.46, and may be used in the research of chronic myelogenous leukemia. BCR-ABL-IN-1 Chemical Structure
  9. GC33368 BCR-ABL-IN-2 BCR-ABL-IN-2 is an inhibitor of BCR-ABL1 tyrosine kinase, with IC50s of 57 nM, 773 nm for ABL1native and ABL1T315I, respectively. BCR-ABL-IN-2 Chemical Structure
  10. GC73614 BCR-ABL-IN-8 BCR-ABL-IN-8 (compound 26f) is a BCR-ABL inhibitor containing trimethoxy group. BCR-ABL-IN-8 Chemical Structure
  11. GC13343 Bosutinib (SKI-606)

    SKI 606

     Bosutinib (SKI-606) is an oral Src/Abl tyrosine kinase inhibito with IC50 of 1.2 nM and 1 nM, respectively. Bosutinib (SKI-606) Chemical Structure
  12. GC40080 Bosutinib-d8

    SKI-606 D8

     Bosutinib-d8 is intended for use as an internal standard for the quantification of bosutinib by GC- or LC-MS. Bosutinib-d8 Chemical Structure
  13. GC35651 Cenisertib

    AS-703569; R-763

     Cenisertib (AS-703569) is an ATP-competitive multi-kinase inhibitor that blocks the activity of Aurora-kinase-A/B, ABL1, AKT, STAT5 and FLT3. Cenisertib induces major growth-inhibitory effects by blocking the activity of several different molecular targets in neoplastic mast cells (MC). Cenisertib inhibits tumor growth in xenograft models of pancreatic, breast, colon, ovarian, and lung tumors and leukemia. Cenisertib Chemical Structure
  14. GC35682 CHMFL-ABL/KIT-155

    CHMFL-ABL-KIT-155

     CHMFL-ABL/KIT-155 (CHMFL-ABL-KIT-155; compound 34) is a highly potent and orally active type II ABL/c-KIT dual kinase inhibitor (IC50s of 46 nM and 75 nM, respectively), and it also presents significant inhibitory activities to BLK (IC50=81 nM), CSF1R (IC50=227 nM), DDR1 (IC50=116 nM), DDR2 (IC50=325 nM), LCK (IC50=12 nM) and PDGFRβ (IC50=80 nM) kinases. CHMFL-ABL/KIT-155 (CHMFL-ABL-KIT-155) arrests cell cycle progression and induces apoptosis. CHMFL-ABL/KIT-155 Chemical Structure
  15. GC35753 CT-721 CT-721 is a potent and time-dependent Bcr-Abl kinase inhibitor with an IC50 of 21.3 nM for wild-type Bcr-Abl kinase, and possesses anti-chronic myeloid leukemia (CML) activities. CT-721 Chemical Structure
  16. GC33351 CZC-8004 (CZC-00008004)

    Dianilinopyrimidine-01

     CZC-8004 (CZC-00008004) (CZC-00008004), an aminopyrimidine, is a pan-kinase inhibitor. CZC-8004 (CZC-00008004) can bind a range of tyrosine kinases, including EGFR and VEGFR2 with IC50 values of 650 and 437 nM, respectively. CZC-8004 (CZC-00008004) Chemical Structure
  17. GC35812 Dasatinib hydrochloride A potent and dual AblWT/Src inhibitor Dasatinib hydrochloride Chemical Structure
  18. GC15884 Dasatinib Monohydrate Inhibitor of ABL, SRC, KIT, PDGFR, and other tyrosine kinases. Dasatinib Monohydrate Chemical Structure
  19. GC14007 DCC-2036 (Rebastinib)

    DCC-2036

     DCC-2036 (Rebastinib) (DCC-2036) is an orally active, non-ATP-competitiveBcr-Abl inhibitor for Abl1WT and Abl1T315I with IC50s of 0.8 nM and 4 nM, respectively. DCC-2036 (Rebastinib) also inhibits SRC, KDR, FLT3, and Tie-2, and has low activity to seen towards c-Kit. DCC-2036 (Rebastinib) Chemical Structure
  20. GC35897 DPH A potent cell permeable c-Abl activator DPH Chemical Structure
  21. GC32867 Flumatinib (HHGV678)

    HH-GV-678

     Flumatinib (HHGV678) (HHGV678) is an orally available, selective inhibitor of Bcr-Abl. Flumatinib (HHGV678) inhibits c-Abl, PDGFRβ and c-Kit with IC50s of 1.2 nM, 307.6 nM and 665.5 nM, respectively. Flumatinib (HHGV678) Chemical Structure
  22. GC13914 Flumatinib mesylate PDGRFβ inhibitor Flumatinib mesylate Chemical Structure
  23. GC36167 GMB-475 GMB-475 is a degrader of BCR-ABL1 tyrosine kinase based on PROTAC, overcoming BCR-ABL1-dependent drug resistance. GMB-475 targets BCR-ABL1 protein and recruits the E3 ligase Von Hippel Lindau (VHL), resulting in ubiquitination and subsequent degradation of the oncogenic fusion protein. GMB-475 Chemical Structure
  24. GC10858 GNF 2

    Bcr-Abl Inhibitor

     Bcr-Abl inhibitor GNF 2 Chemical Structure
  25. GC15079 GNF 5 Bcr-Abl inhibitor GNF 5 Chemical Structure
  26. GC10607 GNF-7

    Type II Bcr-Abl inhibitor

     GNF-7 Chemical Structure
  27. GC10915 GZD824

    GZD824 dimesylate; HQP1351 dimesylate

     Olverembatinib (GZD824) dimesylate is a potent and orally active pan-Bcr-Abl inhibitor. GZD824 potently inhibits a broad spectrum of Bcr-Abl mutants. GZD824 strongly inhibits native Bcr-Abl and Bcr-AblT315I with IC50s of 0.34 nM and 0.68 nM, respectively. GZD824 has antitumor activity. GZD824 Chemical Structure
  28. GC33201 GZD856 GZD856 formic is a potent and orally active PDGFRα/β inhibitor, with IC50s of 68.6 and 136.6 nM, respectively. GZD856 formic is also a Bcr-AblT315I inhibitor, with IC50s of 19.9 and 15.4?nM for native Bcr-Abl and the T315I mutant. GZD856 formic has antitumor activity. GZD856 Chemical Structure
  29. GC71477 HG-7-86-01 HG-7-86-01 (Compound 26) is type II tyrosine kinase inhibitor. HG-7-86-01 Chemical Structure
  30. GC10314 Imatinib (STI571) Imatinib (STI571) (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively. Imatinib (STI571) also is an inhibitor of SARS-CoV and MERS-CoV. Imatinib (STI571) Chemical Structure
  31. GC11759 Imatinib Mesylate (STI571)

    CGP57148B, STI571

     Imatinib Mesylate (STI571) (STI571 Mesylate) is a tyrosine kinases inhibitor that inhibits c-Kit, Bcr-Abl, and PDGFR (IC50=100 nM) tyrosine kinases. Imatinib Mesylate (STI571) Chemical Structure
  32. GC69418 Lyn-IN-1

    Bafetinib analog

    Lyn-IN-1 (Bafetinib analog) is a highly active dual inhibitor of Bcr-Abl and Lyn.

     Lyn-IN-1 Chemical Structure
  33. GC25669 Nilotinib hydrochloride

    AMN-107 HCl

     Nilotinib hydrochloride (AMN-107) is the hydrochloride salt form of nilotinib, an orally bioavailable Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity. Nilotinib hydrochloride Chemical Structure
  34. GC14075 Nocodazole

    NSC 238159, Oncodazole, R 17934

     Nocodazole is an anti-mitotic drug and a rapid and reversible microtubule polymerization inhibitor. It inhibits Abl, Abl (E255K), and Abl (T315I) in cell-free assays with IC50 values of 0.21μM, 0.53μM, and 0.64μM, respectively. Nocodazole Chemical Structure
  35. GC36807 ON 146040 ON 146040 is a potent PI3Kα and PI3Kδ (IC50≈14 and 20 nM, respectively) inhibitor. ON 146040 also inhibits Abl1 (IC50<150 nM). ON 146040 Chemical Structure
  36. GC12637 PD 180970 P210bcr/abl tyrosine kinase inhibitor PD 180970 Chemical Structure
  37. GC72924 PD173952 PD173952 is a tyrosine kinases inhibitor with IC50s of 0.3, 1.7 and 6.6 nM against Lyn, Abl and Csk, respectively. PD173952 Chemical Structure
  38. GC13592 PD173955 Dual Src/Abl kinase inhibitor, ATP-competitive, PD173955 Chemical Structure
  39. GC14396 Ponatinib (AP24534)

    AP 24534

     Ponatinib (AP24534) (AP24534) is an orally active multi-targeted kinase inhibitor with IC50s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively. Ponatinib (AP24534) Chemical Structure
  40. GC45828 Ponatinib-d8 An internal standard for the quantification of ponatinib Ponatinib-d8 Chemical Structure
  41. GC12779 PPY A Abl kinases inhibitor PPY A Chemical Structure
  42. GC73444 PROTAC BCR-ABL Degrader-1 PROTAC BCR-ABL Degrader-1 (compound PROTAC 1) is a PROTAC with a 2-oxoetl linker. PROTAC BCR-ABL Degrader-1 Chemical Structure
  43. GC11140 Radotinib(IY-5511)

    IY-5511

     Bcr-Abl tyrosine kinase inhibitor Radotinib(IY-5511) Chemical Structure
  44. GC73201 Risvodetinib

    IkT-148009

     Risvodetinib (IkT-148009) is an oral, selective and brain-penetrant protein tyrosine kinase inhibitor, displaying target efficacy against c-Abl1, c-Abl2/Arg with IC50 values of 33 nM, 14 nM. Risvodetinib Chemical Structure
  45. GC15197 Saracatinib (AZD0530)

    AZD 0530

     Saracatinib (AZD0530) (AZD0530) is a potent Src family inhibitor with IC50s of 2.7 to 11 nM for c-Src, Lck, c-YES, Lyn, Fyn, Fgr, and Blk. Saracatinib (AZD0530) shows high selectivity over other tyrosine kinases. Saracatinib (AZD0530) Chemical Structure
  46. GC73377 SIAIS100 TFA SIAIS100 TFA is a potent BCR-ABL PROTAC degrader with an DC50 value of 2.7 nM. SIAIS100 TFA Chemical Structure
  47. GC65592 SNIPER(ABL)-020 SNIPER(ABL)-020, conjugating Dasatinib (ABL inhibitor) to Bestatin (IAP ligand) with a linker, induces the reduction of BCR-ABL protein. SNIPER(ABL)-020 Chemical Structure
  48. GC70110 Vamotinib

    PF-114

    Vamotinib (PF-114) is an effective, selective and orally active tyrosine kinase inhibitor. Vamotinib inhibits the self-phosphorylation of BCR/ABL and BCR/ABL-T315I. Vamotinib induces apoptosis. Vamotinib exhibits anti-proliferative and anti-tumor activity. Vamotinib has potential in the study of resistant Philadelphia chromosome-positive (Ph+) leukemia.

     Vamotinib Chemical Structure
  49. GC10970 WP1130

    WP 1130; WP-1130

     WP1130 (WP1130) is a cell-permeable deubiquitinase (DUB) inhibitor, directly inhibiting DUB activity of USP9x, USP5, USP14, and UCH37. WP1130 has been shown to downregulate the antiapoptotic proteins Bcr-Abl and JAK2. WP1130 Chemical Structure

48 Item(s)

per page

Set Descending Direction